Affinergy is a biotechnology company specializing in the development of novel diagnostics for cells, protein biomarkers, and drugs. The company operates in the healthcare diagnostics market and serves a diverse range of clients, including healthcare providers and research institutions. Affinergy's business model revolves around leveraging licensed technology from Duke University to create and commercialize biological delivery systems. The company holds exclusive worldwide patent rights to all its developed technologies, ensuring a competitive edge in the market. Affinergy generates revenue through the sale of its diagnostic products and potential licensing agreements. One of its key innovations is a lateral flow test for detecting the presence of the APOL1 G0 variant in blood, which is crucial for improving kidney transplantation success. Additionally, Affinergy is developing diagnostic assays for autoimmune diseases such as Scleroderma, Lupus, Amyotrophic Lateral Sclerosis, Multiple Sclerosis, and Vasculitis. These assays aim to provide clear diagnostic criteria, thereby facilitating timely diagnosis and treatment.

Keywords: biotechnology, diagnostics, protein biomarkers, drug development, healthcare, autoimmune diseases, kidney transplantation, lateral flow test, Duke University, patent rights.